Pacific Biosciences of California (NasdaqGS:PACB) FY Conference November 19, 2025 11:00 AM ET Company ParticipantsJim Gibson - CFOConference Call ParticipantsNone - Analyst 1None - Analyst 2None - Analyst 3ModeratorAll right. We can start a minute or two later.Jim GibsonSure.Are you guys doing a Q&A style thing, or what do you guys say?I have some prepared. If you guys have questions, I mean, absolutely hop in. Do you?I mean, I've got some stuff I'd like to know. I don't know. It's up to you. I'm just kind ...

Pacific Biosciences of California (NasdaqGS:PACB) 2025 Conference November 18, 2025 08:40 AM ET Company ParticipantsJim Gibson - CFODoug Shankle - Head of Tools, Diagnostics and LabsDoug ShankleHey, everybody. I'm Doug Shankle from Wolfe Research. I lead our tools, diagnostics, and labs effort here. It's my pleasure to welcome Jim Gibson, Chief Financial Officer of Pacific Biosciences. Thanks for being here, Jim.Jim GibsonOf course. My pleasure. Always love coming to New York.Doug ShankleWe were talking abo ...

Core Insights - Webull has launched Vega, an AI-powered decision partner designed to provide personalized insights and analysis for investors, enhancing their trading experience [1][2][3] Group 1: Product Features - Vega offers real-time, personalized insights that help investors understand market movements in relation to their specific circumstances [2] - Key features of Vega include Options Statistics Insights, Data Summary, Portfolio Review, Plain-Language Orders, and Vega Insights, all aimed at improving decision-making for investors [5] - The platform is available at no cost to users, reinforcing Webull's mission to democratize access to investment intelligence [3] Group 2: Company Overview - Webull is a leading online investment platform that provides users with advanced tools and real-time market data, enabling low-cost trading across various asset classes [4][7] - The company serves over 24 million registered users globally, offering access to financial markets 24/7 [7] - Webull operates in 14 markets across North America, Asia Pacific, Europe, and Latin America, integrating market data, community, and educational resources for retail investors [7]

Core Insights - PacBio has introduced new SPRQ-Nx sequencing chemistry aimed at providing a comprehensive view of the genome for under $300, significantly reducing costs for large-scale operations by up to 40% [2][3] - The advancements include multiomic capabilities and compliance features for regulated research environments, enhancing the accessibility of HiFi sequencing for various applications [2][4] Cost Reduction and Technology Advancements - The new SPRQ-Nx chemistry allows for sequencing costs to drop to less than $300 per genome, with beta testing set to begin in November 2025 and full commercial availability planned for 2026 [2][3] - Beta participants will have the opportunity to purchase sequencing reagents for approximately $250 per genome, making it the most affordable option in the market [3] Multiomic and Epigenetic Capabilities - The updates include 5hmC detection for epigenetic profiling, which will be integrated into the Vega platform alongside the SPRQ-Nx chemistry in 2026 [2][4] - These enhancements are designed to support high-demand applications, including rapid sequencing runs for plasmid and targeted sequencing [4] Market Demand and Future Support - There is an increasing demand for HiFi data in large-scale population studies, with PacBio committing to long-term support for the Revio and Vega platforms through 2032 [5] - The company anticipates that the new pricing structure will enable researchers to leverage HiFi data for a broader range of applications, particularly those requiring large sample sizes for robust AI models [4][5]

Core Insights - Hut 8 Corp. reported strong financial results for the second quarter of 2025, highlighting a significant shift in its asset commercialization strategy and a focus on long-term contracts [2][5][11] - The company achieved a revenue of $41.3 million, net income of $137.5 million, and an Adjusted EBITDA of $221.2 million, marking a substantial improvement compared to the previous year [5][12][13] Financial Performance - Revenue for the second quarter of 2025 was $41.3 million, up from $35.2 million in the same period last year, with contributions from Power ($5.5 million), Digital Infrastructure ($1.5 million), and Compute ($34.3 million) [11][12] - Net income for the quarter was $137.5 million, a significant recovery from a loss of $72.2 million in the prior year, driven by gains on digital assets [12][29] - Adjusted EBITDA reached $221.2 million, compared to a loss of $57.5 million in the previous year, indicating a strong operational turnaround [13][22] Asset Management and Strategy - The total energy capacity under management was reported at 1,020 megawatts (MW) as of June 30, 2025, with a development pipeline of approximately 10,800 MW, including 3,100 MW under exclusivity [5][6][10] - The company has commercialized nearly 90% of its energy capacity under long-term contracts, a significant increase from less than 30% a year ago [2][6] - Hut 8's strategic Bitcoin reserve expanded to 10,667 Bitcoin, valued at approximately $1.1 billion as of June 30, 2025 [5][12] Innovations and Partnerships - The launch of American Bitcoin as a dedicated anchor tenant for Hut 8's Power and Digital Infrastructure segments reflects the company's evolving partnerships with major players like BITMAIN, Macquarie, Coinbase, and Anchorage [2][6] - The Vega facility, designed in-house, is positioned as a prototype for next-generation AI infrastructure, showcasing the company's commitment to innovation [2][7] Future Outlook - Hut 8 is advancing its AI data center development opportunities, with a focus on a 592-acre campus in Louisiana, indicating a strategic move towards high-performance computing [6][12] - The company is also preparing for a go-public transaction for American Bitcoin, which is expected to enhance its market presence and operational capabilities [13][18]

Financial Performance - PacBio Q1 2025 revenue was $37.2 million[9,43], a decrease of 8% year-over-year compared to $38.8 million in Q1 2024[47] - Q1 2025 consumable revenue reached a company record of $20.1 million, representing a 26% year-over-year growth[14] - The company's Q1 2025 non-GAAP gross margin was approximately 40%, an increase from approximately 33% in Q1 2024[50] - Non-GAAP operating expenses for Q1 2025 were $61.7 million, a 29% decrease compared to Q1 2024[50] - PacBio anticipates revenue between $150 million and $170 million for 2025, representing approximately 4% growth at the midpoint[20,55] Product and System Updates - Q1 instrument revenue was $11.0 million, lower year-over-year due to increased uncertainty in academic funding[9] - PacBio shipped 12 Revio systems and 28 Vega systems in Q1 2025[9] - Approximately 50% of Revio and Vega systems were shipped to new customers[9,28] - The annualized Revio pull-through for Q1 2025 was $236,000[14,43] - Nearly 90% of Revio reagent kit shipments in Q1 2025 utilized SPRQ chemistry[23] Strategic Initiatives - PacBio implemented a restructuring plan in April, expecting to lower annualized non-GAAP operating expenses by $45 million to $50 million by year-end[21]

Core Insights - PacBio has licensed advanced deep learning-based DNA methylation detection methods from The Chinese University of Hong Kong (CUHK) to enhance its HiFi sequencing capabilities, specifically for detecting 5-hydroxymethylcytosine (5hmC), hemimethylated 5-methylcytosine (5mC), and N6-methyladenine (6mA) [1][2][4] Technology and Innovation - The licensed technology includes the Holistic Kinetic Model 2 (HK2), which utilizes an AI deep learning framework to improve the accuracy of methylation detection, including the ability to call native 5hmC in single molecules, a first for HiFi sequencing [2][4] - HiFi sequencing on Revio and Vega platforms allows for comprehensive genome and epigenome readouts from native DNA without chemical conversion or additional sample preparation, enhancing the efficiency of sequencing workflows [3][6] Market Impact - The integration of HK2 is expected to set a new standard for accuracy in DNA methylation detection, particularly for 5mC and 5hmC, which are crucial for research in cancer and human development [4][7] - Institutions like Children's Mercy Kansas City and GeneDx are already utilizing HiFi sequencing for genomic and epigenomic profiling, indicating a growing adoption of this technology in clinical settings [5] Future Prospects - The new capabilities from HK2 will be delivered to existing customers through software updates, ensuring no additional costs or changes to current sequencing protocols [3][8] - The ability to profile 5hmC is anticipated to open new avenues in liquid biopsy and cancer detection, maintaining DNA integrity and supporting haplotype-resolved analysis [6][8]